Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.

Nature - 19 Feb 2015

Meng Linyan, Ward Amanda J, Chun Seung, Bennett C Frank, Beaudet Arthur L, Rigo Frank

Abstract excerpt

Angelman syndrome is a single-gene disorder characterized by intellectual disability, developmental delay, behavioural uniqueness, speech impairment, seizures and ataxia. It is caused by maternal deficiency of the imprinted gene UBE3A, encoding an E3 ubiquitin ligase. All patients carry at least one copy of paternal UBE3A, which is intact but silenced by a nuclear-localized long non-coding RNA, UBE3A antisense...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angelman Syndrome
Share to Fathers
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Imprinting

Share to Memory Disorders

Share to Oligonucleotides, Antisense

Share to RNA, Antisense

Share to RNA, Long Noncoding

Source

Open in PubMed Open full text

Identifiers

PMID: 25470045
DOI: 10.1038/nature13975
PMCID: PMC4351819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.PMID 25470045Read ↗

Development of an ASO therapy for Angelman syndrome by targeting an evolutionarily conserved region at the start of the <i>UBE3A-AS</i> transcriptSemantic proximity Read ↗

Ube3a unsilencer for the potential treatment of Angelman syndromeSemantic proximity Read ↗

An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript.Semantic proximity Read ↗

Truncation of Ube3a-ATS Unsilences Paternal Ube3a and Ameliorates Behavioral Defects in the Angelman Syndrome Mouse ModelSemantic proximity Read ↗

UBE3A reinstatement as a disease‐modifying therapy for Angelman syndromeSemantic proximity Read ↗

CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in miceSemantic proximity Read ↗

Antisense oligonucleotides targeting <i>UBE3A-ATS</i> restore expression of <i>UBE3A</i> by relieving transcriptional interferenceSemantic proximity Read ↗

Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman SyndromeSemantic proximity Read ↗

Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA.Semantic proximity Read ↗

Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice.Semantic proximity Read ↗

Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3aSemantic proximity Read ↗

[From pathogenesis to treatment of genetic intellectual disabilities: a lesson from Angelman syndrome research].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.